Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Clinical trial NCT05458674 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05458674
Sponsor: Criterium, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

Start date: 2024-01-30
Primary completion: 2027-06-01
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.